HERON THERAPEUTICS, INC. /DE/
HRTX · XNASCIK 818033fmd_1RNBHE3QMZ1M8D2967369N34PWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 31 | 77 | 146 | 89 | 86 | 108 | 127 | 144 | 155 |
| Cost of revenue | 0 | 5 | 28 | 62 | 36 | 46 | 55 | 65 | 39 | 41 |
| Gross profit | 1 | 26 | 50 | 84 | 52 | 40 | 53 | 62 | 106 | 114 |
| Research and development | 103 | 139 | 140 | 167 | 175 | 131 | 83 | 39 | 17 | 12 |
| Selling, general and administrative | 69 | 82 | 94 | 128 | 106 | 127 | 145 | 133 | 100 | 104 |
| Total operating expenses | 172 | 225 | 261 | – | – | – | – | – | – | – |
| Operating income | (171) | (195) | (184) | (211) | (228) | (218) | (175) | (111) | (12) | (3) |
| Interest expense | 3 | 4 | 3 | 1 | 2 | 2 | 2 | 4 | 6 | 10 |
| Interest and investment income | 0 | 1 | 6 | 7 | 4 | 0 | 2 | 3 | 4 | 2 |
| Other non-operating income (expense) | (2) | (3) | 5 | 6 | 1 | (3) | (7) | 0 | (2) | (18) |
| Income before taxes | – | – | – | – | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (173) | (197) | (179) | (205) | (227) | (221) | (182) | (111) | (14) | (20) |